Literature DB >> 19445485

Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging.

Jatinder S Josan1, David L Morse, Liping Xu, Maria Trissal, Brenda Baggett, Peg Davis, Josef Vagner, Robert J Gillies, Victor J Hruby.   

Abstract

A general solid-phase synthetic strategy is developed to prepare fluorescent and/or lanthanide-labeled derivatives of the delta-opioid receptor (deltaOR) ligand H-Dmt-Tic-Lys(R)-OH. The high delta-OR affinity (K(i) = 3 nM) and desirable in vivo characteristics of the Cy5 derivative 1 suggest its usefulness for structure-function studies and receptor localization and as a high-contrast noninvasive molecular marker for live imaging ex vivo or in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19445485      PMCID: PMC2756606          DOI: 10.1021/ol900200k

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  29 in total

1.  Binding and internalization of fluorescent opioid peptide conjugates in living cells.

Authors:  S Arttamangkul; V Alvarez-Maubecin; G Thomas; J T Williams; D K Grandy
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

2.  A solid-phase synthetic strategy for labeled peptides: synthesis of a biotinylated derivative of the delta opioid receptor antagonist TIPP (Tyr-Tic-Phe-Phe-OH).

Authors:  Vivek Kumar; Jane V Aldrich
Journal:  Org Lett       Date:  2003-03-06       Impact factor: 6.005

Review 3.  Attacking pain at its source: new perspectives on opioids.

Authors:  Christoph Stein; Michael Schäfer; Halina Machelska
Journal:  Nat Med       Date:  2003-08       Impact factor: 53.440

4.  Biological properties of a new fluorescent biphalin fragment analogue.

Authors:  Andrzej W Lipkowski; Aleksandra Misicka; Dariusz Kosson; Piotr Kosson; Magdalena Lachwa-From; Agnieszka Brodzik-Bienkowska; Victor J Hruby
Journal:  Life Sci       Date:  2002-01-11       Impact factor: 5.037

5.  The expression of delta- and kappa-opioid receptor is enhanced during intestinal inflammation in mice.

Authors:  Olga Pol; José R Palacio; Margarita M Puig
Journal:  J Pharmacol Exp Ther       Date:  2003-04-30       Impact factor: 4.030

Review 6.  Opioid peptides in cancer.

Authors:  Jakub Fichna; Anna Janecka
Journal:  Cancer Metastasis Rev       Date:  2004 Aug-Dec       Impact factor: 9.264

Review 7.  Dmt and opioid peptides: a potent alliance.

Authors:  Sharon D Bryant; Yunden Jinsmaa; Severo Salvadori; Yoshio Okada; Lawrence H Lazarus
Journal:  Biopolymers       Date:  2003       Impact factor: 2.505

8.  PET imaging of human cardiac opioid receptors.

Authors:  Patricia S R Villemagne; Robert F Dannals; Hayden T Ravert; J James Frost
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08-01       Impact factor: 9.236

9.  Synthesis of a potent and selective (18)F-labeled delta-opioid receptor antagonist derived from the Dmt-Tic pharmacophore for positron emission tomography imaging.

Authors:  Eun Kyoung Ryu; Zhanhong Wu; Kai Chen; Lawrence H Lazarus; Ewa D Marczak; Yusuke Sasaki; Akihiro Ambo; Severo Salvadori; Chuancheng Ren; Heng Zhao; Gianfranco Balboni; Xiaoyuan Chen
Journal:  J Med Chem       Date:  2008-03-01       Impact factor: 7.446

10.  Highly potent fluorescent analogues of the opioid peptide [Dmt1] DALDA.

Authors:  Irena Berezowska; Nga N Chung; Carole Lemieux; Bogumil Zelent; Hazel H Szeto; Peter W Schiller
Journal:  Peptides       Date:  2003-08       Impact factor: 3.750

View more
  12 in total

1.  Delta-Opioid Receptor (δOR) Targeted Near-Infrared Fluorescent Agent for Imaging of Lung Cancer: Synthesis and Evaluation In Vitro and In Vivo.

Authors:  Allison S Cohen; Renata Patek; Steven A Enkemann; Joseph O Johnson; Tingan Chen; Eric Toloza; Josef Vagner; David L Morse
Journal:  Bioconjug Chem       Date:  2015-10-30       Impact factor: 4.774

Review 2.  The evolving small-molecule fluorescent-conjugate toolbox for Class A GPCRs.

Authors:  Andrea J Vernall; Stephen J Hill; Barrie Kellam
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

3.  Fluorescent and lanthanide labeling for ligand screens, assays, and imaging.

Authors:  Jatinder S Josan; Channa R De Silva; Byunghee Yoo; Ronald M Lynch; Mark D Pagel; Josef Vagner; Victor J Hruby
Journal:  Methods Mol Biol       Date:  2011

Review 4.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

Review 5.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

6.  Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.

Authors:  Amanda Shanks Huynh; Veronica Estrella; Valerie E Stark; Allison S Cohen; Tingan Chen; Todd J Casagni; Jatinder S Josan; Mark C Lloyd; Joseph Johnson; Jongphil Kim; Victor J Hruby; Josef Vagner; David L Morse
Journal:  Mol Pharm       Date:  2016-01-08       Impact factor: 4.939

7.  Heterobivalent ligands target cell-surface receptor combinations in vivo.

Authors:  Liping Xu; Jatinder S Josan; Josef Vagner; Michael R Caplan; Victor J Hruby; Eugene A Mash; Ronald M Lynch; David L Morse; Robert J Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

8.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

9.  Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells.

Authors:  Amanda Shanks Huynh; Dominique F Abrahams; Monica S Torres; Margaret K Baldwin; Robert J Gillies; David L Morse
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

10.  The role of tumor tissue architecture in treatment penetration and efficacy: an integrative study.

Authors:  Katarzyna A Rejniak; Veronica Estrella; Tingan Chen; Allison S Cohen; Mark C Lloyd; David L Morse
Journal:  Front Oncol       Date:  2013-05-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.